SCHEMBL3815028

SCHEMBL3815028

Nc1ccc(-c2csc(-c3cnccc3C(F)(F)F)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.47
AR P10275 2/20 0.47
TDP1 Q9NUW8 1/20 0.46
RAB9A P51151 6/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 3/20 0.43
NPC1 O15118 2/20 0.43
KMT2A Q03164 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MPL P40238 1/20 0.43
CYP19A1 P11511 5/20 0.43
ALDH1A1 P00352 2/20 0.43
SREBF2 Q12772 1/20 0.43
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
AXL P30530 1/20 0.41
PBRM1 Q86U86 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786537 0.87 KDM4E (0.61) KDM4EARTDP1RAB9ASMN1; SMN2
SCHEMBL3816057 0.85 TSHR (0.48) KDM4EARTDP1RAB9ANPC1
SCHEMBL3821159 0.84 KDM4E (0.45) KDM4EARTDP1SMN1; SMN2LMNA
SCHEMBL3819669 0.84 KDM4E (0.54) KDM4EARTDP1RAB9ASMN1; SMN2
SCHEMBL6781128 0.84 CDC25A (0.49) KDM4EARTDP1RAB9ASMN1; SMN2
SCHEMBL3815420 0.83 KDM4E (0.55) KDM4EARTDP1RAB9ASMN1; SMN2
SCHEMBL3814242 0.79 RAB9A (0.49) KDM4EARTDP1RAB9ASMN1; SMN2
SCHEMBL3812816 0.79 HPGD (0.53) KDM4ETDP1RAB9ALMNANPC1
SCHEMBL3823493 0.79 RAB9A (0.64) KDM4ETDP1RAB9ASMN1; SMN2LMNA
SCHEMBL12601790 0.79 S1PR1 (0.46) KDM4EARTDP1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1348706-B1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-08-19 EP disclosed
US-7067537-B2 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-27 US disclosed
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-15 US disclosed
EP-1348706-A1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof CYP17A1, CYP21A2, HSD17B1 KDM4E 1126/4885AR 58/4885TDP1 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.